Reuters (01/03/12) Scheer, Steven
Jeremy Levin, who will take over as CEO for Teva Pharmaceutical Industries in May, has expressed an intention to shift the focus from generics to branded drugs. Levin had been senior vice president for strategy, alliances and transactions at Bristol-Meyers Squibb since 2007 and was part of a management team that turned around that company, and is expected to transfer his successful strategy to Teva. The change is expected to take time, as it is unlikely Levin will find a group of winning new drugs to build Teva's branded portfolio in a short span. Teva does have around 30 branded drugs currently in various development or clinical trial stages. Analysts do not expect further large acquisitions like those that made Teva the largest generics manufacturer, but they do expect fewer big generics to enter the market starting in 2013. Teva will be focusing on developing its branded drugs portfolio and on expanding into emerging markets.

Read the complete article